Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company`s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Website: cullinanoncology.com



Growth: Bad revenue growth rate -94.7%, there is slowdown compared to average historical growth rates -33.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.25 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -70.3% (LTM)

Entry Point: Share price is 1.2% higher than minimum and 76.2% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: CGEM
Share price, USD:  (+1.2%)6.99
year average price 10.56  


year start price 17.98 2024-09-08

max close price 18.25 2024-09-09

min close price 6.91 2025-09-04

current price 6.99 2025-09-08
Common stocks: 44 782 500

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 313
Net Debt ($m): -74
EV (Enterprise Value): 239
Price to Book: 0.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-15seekingalpha.com

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst

2025-06-01prnewswire.com

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

2025-05-22globenewswire.com

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

2025-05-01zacks.com

Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know

2025-01-09seekingalpha.com

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

2025-01-08seekingalpha.com

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

2024-11-05globenewswire.com

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

2024-09-14globenewswire.com

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

2024-06-01globenewswire.com

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

2024-05-23globenewswire.com

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CGEM CGEM CGEM CGEM CGEM CGEM CGEM CGEM CGEM
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-05-15 2024-03-14 2023-11-08 2023-08-10 2023-05-11 2023-03-09 2022-11-14
acceptedDate 2024-11-07 07:18:20 2024-08-08 07:20:06 2024-05-15 16:31:36 2024-03-14 07:22:00 2023-11-08 07:22:35 2023-08-10 07:44:59 2023-05-11 16:14:13 2023-03-09 07:18:08 2022-11-14 07:20:31
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0 0 0 0
costOfRevenue 0 77 000 76 000 77 000 80 000 81 000 0 0 0
grossProfit 0 -77 000 -76 000 -77 000 -80 000 -81 000 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 36M 36M 31M 35M 34M 27M 52M 21M 20M
generalAndAdministrativeExpenses 13M 14M 12M 11M 11M 10M 11M 11M 10M
sellingAndMarketingExpenses 0 -77 000 -76 000 -77 000 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 13M 14M 12M 11M 11M 10M 11M 11M 10M
otherExpenses 0 -72 000 -44 000 -117 000 180 000 69 000 107 000 298 000 0
operatingExpenses 49M 50M 43M 45M 45M 38M 63M 33M 30M
costAndExpenses 49M 50M 43M 45M 45M 38M 63M 33M 30M
interestIncome 8M 8M 6M 6M 6M 5M 5M 3M 2M
interestExpense 0 0 0 0 0 0 -5M -3M 2M
depreciationAndAmortization 76 000 77 000 76 000 77 000 80 000 81 000 72 000 59 000 9000
ebitda -49M -50M -43M -45M -44M -38M -63M -33M -30M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -49M -50M -43M -45M -45M -38M -63M -33M -30M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 8M 8M 6M 6M -260 000 69 000 5M 4M 2M
incomeBeforeTax -41M -42M -37M -40M -39M -32M -58M -29M -27M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 -192 000 -14M -5M -5M -179 000 -2M -3M
netIncome -41M -42M -37M -24M -39M -32M -58M -27M -25M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -0.7 -0.76 -0.86 -0.56 -0.92 -0.81 -1.42 -0.59 -0.55
epsdiluted -0.7 -0.76 -0.86 -0.56 -0.92 -0.81 -1.42 -0.59 -0.55
weightedAverageShsOut 58M 55M 43M 43M 43M 40M 41M 46M 46M
weightedAverageShsOutDil 58M 55M 43M 43M 43M 40M 41M 46M 46M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CGEM CGEM CGEM CGEM CGEM CGEM CGEM CGEM CGEM
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-05-15 2024-03-14 2023-11-08 2023-08-10 2023-05-11 2023-03-09 2022-11-14
acceptedDate 2024-11-07 07:18:20 2024-08-08 07:20:06 2024-05-15 16:31:36 2024-03-14 07:22:00 2023-11-08 07:22:35 2023-08-10 07:44:59 2023-05-11 16:14:13 2023-03-09 07:18:08 2022-11-14 07:20:31
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 102M 115M 74M 98M 65M 512M 122M 550M 243M
shortTermInvestments 476M 547M 359M 369M 402M 350M 269M 311M 333M
cashAndShortTermInvestments 578M 662M 433M 467M 466M 512M 391M 550M 576M
netReceivables 0 0 0 5M 0 0 0 0 0
inventory 0 0 0 -5M 0 0 0 0 0
otherCurrentAssets 14M 15M 13M 13M 10M 6M 8M 7M 6M
totalCurrentAssets 592M 678M 446M 480M 477M 512M 399M 474M 582M
propertyPlantEquipmentNet 3M 3M 3M 4M 4M 5M 5M 5M 5M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 58M 0 0 0 14M 19M 110M 81M 29M
taxAssets 0 0 0 914 000 0 0 0 0 0
otherNonCurrentAssets 460 000 460 000 460 000 459 000 459 000 -13M 459 000 459 000 460 000
totalNonCurrentAssets 61M 3M 4M 5M 18M 10M 116M 87M 35M
otherAssets 0 0 0 -0 0 0 0 0 0
totalAssets 653M 681M 449M 485M 495M 522M 515M 561M 617M
accountPayables 2M 2M 4M 2M 951 000 2M 2M 3M 2M
shortTermDebt 1M 2M 1M 1M 3M 4M 3M 2M 696 000
taxPayables 0 0 0 0 0 0 4M 4M 11M
deferredRevenue 0 0 0 0 17M 13M 0 0 0
otherCurrentLiabilities 21M 19M 17M 24M 2M 1M 21M 18M 25M
totalCurrentLiabilities 24M 23M 22M 28M 23M 20M 26M 22M 27M
longTermDebt 1M 2M 2M 2M 2M 3M 3M 4M 4M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 914 000 0 0 0 0 0
otherNonCurrentLiabilities 0 0 -1 0 0 0 0 0 2M
totalNonCurrentLiabilities 1M 2M 2M 3M 2M 3M 3M 4M 4M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 2M 3M 2M 2M 4M 4M 5M 5M 5M
totalLiabilities 25M 25M 24M 31M 26M 22M 29M 26M 31M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 6000 6000 4000 4000 4000 4000 4000 5000 5000
retainedEarnings -321M -280M -238M -201M -177M -138M -106M -48M -21M
accumulatedOtherComprehensiveIncomeLoss 970 000 -476 000 -331 000 -129 000 -1M -2M -1M -3M -4M
othertotalStockholdersEquity 947M 937M 664M 655M 647M 639M 593M 585M 611M
totalStockholdersEquity 628M 656M 426M 454M 469M 500M 486M 535M 586M
totalEquity 628M 656M 426M 454M 469M 500M 486M 535M 586M
totalLiabilitiesAndStockholdersEquity 653M 681M 449M 485M 495M 522M 515M 561M 617M
minorityInterest 0 0 0 192 000 0 0 0 0 0
totalLiabilitiesAndTotalEquity 653M 681M 449M 485M 495M 522M 515M 561M 617M
totalInvestments 534M 547M 359M 369M 415M 369M 379M 392M 363M
totalDebt 2M 3M 3M 4M 6M 6M 7M 5M 5M
netDebt -100M -112M -71M -95M -59M -506M -116M -545M -238M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CGEM CGEM CGEM CGEM CGEM CGEM CGEM CGEM CGEM
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-08 2024-05-15 2024-03-14 2023-11-08 2023-08-10 2023-05-11 2023-03-09 2022-11-14
acceptedDate 2024-11-07 07:18:20 2024-08-08 07:20:06 2024-05-15 16:31:36 2024-03-14 07:22:00 2023-11-08 07:22:35 2023-08-10 07:44:59 2023-05-11 16:14:13 2023-03-09 07:18:08 2022-11-14 07:20:31
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -41M -42M -37M -24M -39M -32M -58M -27M -25M
depreciationAndAmortization 76 000 77 000 76 000 77 000 80 000 81 000 72 000 59 000 9000
deferredIncomeTax 0 0 0 -6M 607 000 1M 0 20M 0
stockBasedCompensation 9M 11M 8M 8M 8M 8M 7M 8M 5M
changeInWorkingCapital 7M -1M -6M 3M -181 000 -5M 1M -5M -35M
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 560 000 -2M 1M 2M -2M 461 000 -630 000 1M -2M
otherWorkingCapital 6M 1M -7M 2M 1M -5M 630 000 -6M -33M
otherNonCashItems -10M 9M 4M 897 000 -3M -3M -1M -20M 171 000
netCashProvidedByOperatingActivities -34M -36M -38M -18M -34M -31M -51M -25M -54M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 -49 000 -159 000 -882 000 0
acquisitionsNet 0 0 0 0 0 -12 159 0 -5M 5M
purchasesOfInvestments -97M -325M -131M -66M -137M -81M -89M -160M -124M
salesMaturitiesOfInvestments 117M 140M 144M 117M 94M 94M 104M 133M 61M
otherInvestingActivites 0 -185M 13M 51 470 -42 958 12 159 0 5M -251 000
netCashUsedForInvestingActivites 20M -185M 13M 51M -43M 12M 15M -29M -58M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -4M 266M 1M 248 000 290 000 38M -36 000 -4M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 1M 262M 1M 248 000 -178 000 214 000 2M -29M 1M
netCashUsedProvidedByFinancingActivities 1M 262M 1M 248 000 112 000 39M 2M -33M 1M
effectOfForexChangesOnCash 0 0 0 1 80M -16M 0 0 0
netChangeInCash -13M 41M -24M 34M -77M 20M -34M -87M -111M
cashAtEndOfPeriod 102M 115M 74M 98M 65M 142M 122M 156M 243M
cashAtBeginningOfPeriod 115M 74M 98M 65M 142M 122M 156M 243M 354M
operatingCashFlow -34M -36M -38M -18M -34M -31M -51M -25M -54M
capitalExpenditure 0 0 0 0 0 -49 000 -159 000 -882 000 0
freeCashFlow -34M -36M -38M -18M -34M -31M -51M -26M -54M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-08-08 11:00 ET
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
2024-06-01 11:00 ET
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
2024-05-24 12:00 ET
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
2024-05-23 21:04 ET
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
2024-05-15 20:05 ET
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-04-29 11:00 ET
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
2024-04-24 14:09 ET
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
2024-04-16 11:00 ET
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
2024-04-16 10:59 ET
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
2024-04-16 10:59 ET
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
2024-03-14 11:00 ET
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-01 12:00 ET
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
2024-02-27 13:00 ET
Cullinan Oncology to Participate in Upcoming Investor Conferences
2023-12-18 21:53 ET
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 21:30 ET
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
2023-11-08 12:00 ET
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-11-03 16:01 ET
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
2023-10-30 12:00 ET
Cullinan Oncology to Participate in Upcoming Investor Conferences
2023-09-06 12:00 ET
Cullinan Oncology to Participate in Upcoming Investor Conferences
2023-08-10 11:00 ET
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-08-09 11:00 ET
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
2023-08-03 20:15 ET
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
2023-07-31 12:00 ET
Cullinan Oncology to Participate in Upcoming Investor Conferences
2023-05-25 21:00 ET
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
2023-05-11 20:01 ET
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-04-26 14:08 ET
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
2023-04-20 11:00 ET
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
2023-03-27 11:00 ET
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
2023-03-14 20:35 ET
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
2023-03-09 12:00 ET
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-27 13:00 ET
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
2023-02-14 00:00 ET
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
2023-02-02 21:01 ET
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
2023-02-01 21:41 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-24 13:00 ET
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
2023-01-03 22:13 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-12-02 22:00 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-14 12:00 ET
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-11-02 12:00 ET
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
2022-11-01 21:23 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-01 11:00 ET
Cullinan Oncology to Participate in Upcoming Investor Conferences
2022-10-25 11:00 ET
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
2022-10-03 20:50 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-07 12:00 ET
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference
2022-09-01 21:27 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-15 20:57 ET
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
2022-08-10 11:00 ET
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-08-01 20:55 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-01 12:00 ET
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference
2022-07-05 20:01 ET
Cullinan Oncology to Participate in William Blair Biotech Focus Conference
2022-07-01 20:37 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-23 12:00 ET
Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417
2022-06-01 21:00 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-31 12:00 ET
Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
2022-05-26 12:45 ET
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
2022-05-19 12:00 ET
Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference
2022-05-16 10:45 ET
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results
2022-05-12 06:00 ET
Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
2022-05-02 21:00 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-27 14:00 ET
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
2022-04-05 12:00 ET
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
2022-04-04 20:34 ET
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-28 20:01 ET
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
2022-03-17 11:08 ET
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-17 11:00 ET
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
2022-03-09 13:00 ET
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
2022-03-08 22:30 ET
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
2022-02-28 13:00 ET
Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors
2022-02-07 11:30 ET
Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference
2022-01-10 11:30 ET
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
2022-01-05 14:00 ET
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
2022-01-04 12:00 ET
FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
2021-12-16 11:30 ET
Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients
2021-12-13 12:00 ET
Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients
2021-11-22 17:37 ET
Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference
2021-11-09 11:45 ET
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
2021-10-18 11:00 ET
Cullinan Oncology Appoints Nadim Ahmed as Chief Executive Officer
2021-09-08 20:01 ET
Cullinan Oncology to Participate in Upcoming Investor Conferences
2021-08-10 10:30 ET
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
2021-08-05 20:05 ET
Cullinan Oncology to Participate in the 41st Annual Canaccord Genuity Growth Conference
2021-06-29 12:00 ET
Cullinan Oncology Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors
2021-06-07 12:30 ET
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
2021-06-04 13:00 ET
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
2021-05-21 12:00 ET
Cullinan Oncology Announces Management Transition
2021-05-19 21:00 ET
Cullinan Oncology to Provide CLN-081 Clinical Update at ASCO 2021
2021-05-14 10:30 ET
Cullinan Oncology Reports First Quarter 2021 Financial Results
2021-04-07 14:08 ET
Cullinan Oncology, Inc. to Participate in the 20th Annual Needham Virtual Healthcare Conference
2021-03-30 10:15 ET
Cullinan Oncology Reports Full Year 2020 Financial Results and Business Highlights
2021-03-02 14:48 ET
Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference
2021-02-22 12:30 ET
Cullinan Management, Inc. Announces Business Update
2021-01-13 02:43 ET
Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-01-08 02:02 ET
Cullinan Management Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2025-09-04 10:01 ET
Cullinan Oncology, Inc. published news for 2025 q2
SEC form 8
2025-09-04 10:01 ET
Cullinan Oncology, Inc. published news for 2025 q2
SEC form 10
2025-08-07 11:07 ET
Cullinan Oncology, Inc. reported for 2025 q2
SEC form 8
2025-08-07 11:04 ET
Cullinan Oncology, Inc. published news for 2025 q2
SEC form 8
2025-08-07 11:04 ET
Cullinan Oncology, Inc. reported for 2025 q2
SEC form 8
2025-06-04 20:04 ET
Cullinan Oncology, Inc. published news for 2025 q1
SEC form 8
2025-06-04 20:04 ET
Cullinan Oncology, Inc. published news for 2025 q1
SEC form 8
2025-06-04 20:04 ET
Cullinan Oncology, Inc. published news for 2025 q1
SEC form 10
2025-05-08 11:24 ET
Cullinan Oncology, Inc. reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Cullinan Oncology, Inc. reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Cullinan Oncology, Inc. published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Cullinan Oncology, Inc. reported for 2025 q1
SEC form 10
2025-02-27 07:07 ET
Cullinan Oncology, Inc. reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Cullinan Oncology, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Cullinan Oncology, Inc. published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Cullinan Oncology, Inc. reported for 2024 q4
SEC form 8
2025-01-29 12:00 ET
Cullinan Oncology, Inc. published news for 2024 q4
SEC form 8
2025-01-29 12:00 ET
Cullinan Oncology, Inc. published news for 2024 q4
SEC form 10
2024-11-07 07:18 ET
Cullinan Oncology, Inc. reported for 2024 q3
SEC form 8
2024-11-07 07:06 ET
Cullinan Oncology, Inc. published news for 2024 q3
SEC form 8
2024-11-07 07:06 ET
Cullinan Oncology, Inc. reported for 2024 q3
SEC form 10
2024-08-08 07:20 ET
Cullinan Oncology, Inc. reported for 2024 q2
SEC form 8
2024-08-08 07:15 ET
Cullinan Oncology, Inc. published news for 2024 q2
SEC form 8
2024-08-08 07:15 ET
Cullinan Oncology, Inc. reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Cullinan Oncology, Inc. reported for 2024 q2
SEC form 10
2024-05-15 16:31 ET
Cullinan Oncology, Inc. reported for 2024 q1
SEC form 8
2024-05-15 16:15 ET
Cullinan Oncology, Inc. published news for 2024 q1
SEC form 8
2024-05-15 16:15 ET
Cullinan Oncology, Inc. reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Cullinan Oncology, Inc. reported for 2024 q1
SEC form 10
2024-03-14 07:22 ET
Cullinan Oncology, Inc. reported for 2023 q4
SEC form 8
2024-03-14 07:14 ET
Cullinan Oncology, Inc. published news for 2023 q4
SEC form 8
2024-03-14 07:14 ET
Cullinan Oncology, Inc. reported for 2023 q4
SEC form 10
2024-03-14 00:00 ET
Cullinan Oncology, Inc. reported for 2023 q4
SEC form 8
2024-01-08 16:15 ET
Cullinan Oncology, Inc. published news for 2023 q4
SEC form 10
2023-11-08 07:22 ET
Cullinan Oncology, Inc. reported for 2023 q3
SEC form 8
2023-11-08 07:10 ET
Cullinan Oncology, Inc. reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Cullinan Oncology, Inc. reported for 2023 q3
SEC form 10
2023-08-10 07:44 ET
Cullinan Oncology, Inc. reported for 2023 q2
SEC form 6
2023-08-10 07:07 ET
Cullinan Oncology, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Cullinan Oncology, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Cullinan Oncology, Inc. reported for 2023 q2
SEC form 6
2023-06-14 16:15 ET
Cullinan Oncology, Inc. published news for 2023 q1
SEC form 10
2023-05-11 16:14 ET
Cullinan Oncology, Inc. reported for 2023 q1
SEC form 6
2023-05-11 16:09 ET
Cullinan Oncology, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Cullinan Oncology, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Cullinan Oncology, Inc. reported for 2023 q1
SEC form 6
2023-04-21 07:01 ET
Cullinan Oncology, Inc. published news for 2023 q1
SEC form 10
2023-03-09 07:18 ET
Cullinan Oncology, Inc. reported for 2022 q4
SEC form 6
2023-03-09 07:11 ET
Cullinan Oncology, Inc. reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q4
SEC form 8
2023-03-09 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q4
SEC form 6
2023-02-23 17:06 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2023-02-21 19:01 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2023-02-21 18:57 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2023-02-21 18:53 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2023-02-21 18:51 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2023-02-13 19:11 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2023-01-19 16:40 ET
Cullinan Oncology, Inc. published news for 2022 q4
SEC form 6
2022-11-29 16:05 ET
Cullinan Oncology, Inc. published news for 2022 q3
SEC form 10
2022-11-14 07:20 ET
Cullinan Oncology, Inc. reported for 2022 q3
SEC form 6
2022-11-14 07:18 ET
Cullinan Oncology, Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q3
SEC form 6
2022-11-02 16:34 ET
Cullinan Oncology, Inc. published news for 2022 q3
SEC form 6
2022-11-02 08:28 ET
Cullinan Oncology, Inc. published news for 2022 q3
SEC form 6
2022-10-25 07:14 ET
Cullinan Oncology, Inc. published news for 2022 q3
SEC form 10
2022-08-10 07:24 ET
Cullinan Oncology, Inc. reported for 2022 q2
SEC form 6
2022-08-10 07:20 ET
Cullinan Oncology, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q2
SEC form 6
2022-06-27 16:15 ET
Cullinan Oncology, Inc. published news for 2022 q1
SEC form 6
2022-06-24 16:20 ET
Cullinan Oncology, Inc. published news for 2022 q1
SEC form 10
2022-05-16 07:11 ET
Cullinan Oncology, Inc. published news for 2022 q1
SEC form 6
2022-05-16 06:52 ET
Cullinan Oncology, Inc. published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Cullinan Oncology, Inc. reported for 2022 q1
SEC form 6
2022-05-12 06:11 ET
Cullinan Oncology, Inc. published news for 2022 q1
SEC form 6
2022-04-29 07:00 ET
Cullinan Oncology, Inc. published news for 2022 q1
SEC form 10
2022-03-17 07:31 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 6
2022-03-17 07:20 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 10
2022-03-17 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 8
2022-03-17 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 6
2022-03-03 08:26 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 6
2022-03-02 19:04 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 6
2022-03-02 19:04 ET
Cullinan Oncology, Inc. published news for 2021 q4
SEC form 6
2021-12-29 07:01 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 6
2021-12-16 06:43 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 10
2021-11-09 07:09 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 6
2021-11-09 06:57 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 6
2021-10-20 16:33 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 6
2021-10-18 07:45 ET
Cullinan Oncology, Inc. published news for 2021 q3
SEC form 6
2021-08-10 07:03 ET
Cullinan Oncology, Inc. published news for 2021 q2
SEC form 10
2021-08-10 07:01 ET
Cullinan Oncology, Inc. published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q2
SEC form 8
2021-08-10 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q2
SEC form 6
2021-07-01 09:25 ET
Cullinan Oncology, Inc. published news for 2021 q2
SEC form 6
2021-06-04 09:07 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 6
2021-05-21 16:04 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 10
2021-05-14 06:46 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 6
2021-05-14 06:39 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 10
2021-05-14 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 8
2021-05-14 00:00 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 6
2021-04-29 16:40 ET
Cullinan Oncology, Inc. published news for 2021 q1
SEC form 10
2021-03-30 07:15 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-03-30 06:27 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-02-26 07:04 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-02-22 17:14 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-13 16:06 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:55 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:45 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:42 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:40 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:40 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:40 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:40 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:37 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:37 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:34 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:34 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:32 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:31 ET
Cullinan Oncology, Inc. published news for 2020 q4
SEC form 6
2021-01-07 20:29 ET
Cullinan Oncology, Inc. published news for 2020 q4